NCT06672250

Brief Summary

Research indicates a strong correlation between cancer and thrombosis, with approximately 20% of blood clots in the U.S. being cancer-related, according to CDC data. Cancer patients face a 4-7 times higher risk of thrombosis compared to non-cancer individuals. Certain cancer treatments, such as chemotherapy and targeted therapy, elevate the likelihood of venous thromboembolism (VTE). Cancer patients with VTE exhibit a significantly higher hazard ratio (H.R.) of 3.4 compared to those without VTE. This study aims to explore three main topics: (1) Comparing the differences and similarities of leukocyte populations between cancer-associated thrombosis (CAT) and venous thromboembolism (VTE). (2) Characterizing the factors contributing to increased incidence of cancer-associated thrombosis (CAT), with the hypothesis that circulating tumor microemboli (CTM) may express more thrombosis-related proteins than CTCs. (3) Understanding the effects of aspirin or NOACs on cancer-associated thrombosis and CTM formation.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
12mo left

Started May 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress66%
May 2024Apr 2027

Study Start

First participant enrolled

May 28, 2024

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

October 31, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 4, 2024

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 27, 2026

Expected
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 30, 2027

Last Updated

September 24, 2025

Status Verified

September 1, 2025

Enrollment Period

2 years

First QC Date

October 31, 2024

Last Update Submit

September 19, 2025

Conditions

Tumor Cells, CirculatingVenous Thrombosis

Keywords

CancerThrombosisVenous thromboembolismCirculating tumor cellsEndovascular therapy

Outcome Measures

Primary Outcomes (2)

  • cell culture

    cancer-specific surface markers

    baseline

  • RNA-seq

    DNA/RNA extraction of sorted cells as instruments' maneuvers and do the RNA-seq

    baseline

Study Arms (2)

cancer for CTC culture

a thrombosis patient with cancer .

Procedure: CTCs/CTMs culture

health for CTC culture

a thrombosis patient without cancer

Procedure: CTCs/CTMs culture

Interventions

CTCs/CTMs culturePROCEDURE

Collect the thrombosis from participants underwent catheter-based thrombectomy.To characterized by cancer-specific surface markers successfully and identify within the culture

cancer for CTC culturehealth for CTC culture

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

patients who underwent catheter-based thrombectomy

You may qualify if:

  • age≧18
  • participants (1)participants without cancer: without cancer in five years (2)participants with cancer:pathology reveal have malignant tumor
  • patients who underwent catheter-based thrombectomy
  • agree do the thrombectomy

You may not qualify if:

  • participants without cancer (1).shock (2).severe sepsis (3).with cancer in five years
  • participants with cancer (1).shock (2).severe sepsis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

New Taipei City TuCheng Hospital

New Taipei City, Taiwan

RECRUITING

Related Publications (1)

  • Falanga A, Russo L. Epidemiology, risk and outcomes of venous thromboembolism in cancer. Hamostaseologie. 2012;32(2):115-25. doi: 10.5482/ha-1170. Epub 2011 Oct 5.

    PMID: 21971578RESULT

MeSH Terms

Conditions

Neoplastic Cells, CirculatingVenous ThrombosisNeoplasmsThrombosisVenous Thromboembolism

Condition Hierarchy (Ancestors)

Neoplasm MetastasisNeoplastic ProcessesPathologic ProcessesPathological Conditions, Signs and SymptomsEmbolism and ThrombosisVascular DiseasesCardiovascular DiseasesThromboembolism

Study Officials

  • Hsin-Fu Lee, PhD

    New Taipei City TuCheng Hospital

    STUDY DIRECTOR

Central Study Contacts

Hsin-Fu Lee, PhD

CONTACT

09753661058805033@cgmh.org.tw

Chia-Hsun Hsieh, PhD

CONTACT

0975366137wisdom5000@cgmh.org.tw

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Target Duration
1 Day
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor Attending Physicians

Study Record Dates

First Submitted

October 31, 2024

First Posted

November 4, 2024

Study Start

May 28, 2024

Primary Completion (Estimated)

May 27, 2026

Study Completion (Estimated)

April 30, 2027

Last Updated

September 24, 2025

Record last verified: 2025-09

Locations

TW(1)